Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2020

Study Completion Date

February 28, 2026

Conditions
Peripheral T-cell Lymphomas (PTCL)PTCL-NOSAngioimmunoblastic T-cell Lymphoma (AITL)ALK- Anaplastic Large Cell Lymphoma (ALCL)Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin
Interventions
DRUG

Ro-CHOEP-21 (PHASE I)

"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"

DRUG

Ro-CHOEP-21 (PHASE II)

"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"

Trial Locations (27)

10126

AO Città della Salute e della Scienza - Ematologia 1U, Torino

AO Città della Salute e della Scienza - SC Ematologia, Torino

12100

Azienda Ospedaliera S.Croce e Carle, Cuneo

15121

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria

16321

IRCCS AOU San Martino - Clinica Ematologica, Genova

IRCCS AOU San Martino - UO Ematologia 1, Genova

20089

Istituto Clinico Humanitas, Rozzano

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

20133

"Fondazione IRCCS Istituto Nazionale dei Tumori", Milan

20162

Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan

26123

Spedali Civili, Brescia

27100

Fondazione IRCCS - Policlinico San Matteo, Pavia

28100

Ospedale Maggiore della Carità - SCDU Ematologia, Novara

29121

Ospedale G. Da Saliceto - AUSL di Piacenza, Piacenza

33081

IRCCS Centro di Riferimento Oncologico (CRO), Aviano

33100

"AOU Santa Maria della Misericordia", Udine

37134

Ospedale Borgo Roma, Verona

40138

Policlinico S. Orsola Malpighi, Bologna

42123

"IRCCS Arcispedale Santa Maria Nuova", Reggio Emilia

43100

AOU di Parma, Parma

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola, Meldola

47900

Ospedale degli Infermi, Rimini

48121

UO Ematologia Ospedale S.Maria delle Croci, Ravenna

80131

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli

90146

AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello), Palermo

09121

Ospedale Businco, Cagliari

06132

A.O. di Perugia - Santa Maria della Misericordia, Perugia

All Listed Sponsors
lead

Fondazione Italiana Linfomi - ETS

OTHER

NCT02223208 - Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas | Biotech Hunter | Biotech Hunter